Joints of JointMeno 150mg Laboratorios liconsa prevents and treats osteoporosis after menopause (1 blister x 1 tablet)

Dosage form Box of 1 blister x 1 tablet
Specifications Ibandronic Acid

Ingredient

Composition information	Content
Ibandronic Acid	150mg

Uses

indications

Joints of joints are indicated in the following cases:

Preventing and treating osteoporosis in women after menopause is at risk of increasing fractures. Nitrogen, has a selective effect on bone tissue and especially inhibits the activity of bone cancel cells without directly affecting bone formation. The drug does not interfere with the restoration of cell cancellation. IBANDRONIC acid helps to achieve real bone mass growth and reduces the fracture rate by reducing the rate of bone transfer that has increased during premenopausal periods in postmenopausal women.

Pharmacokinetics

absorption

After drinking, ibandronic acid is quickly absorbed in the small intestine. The concentration in plasma increases linearly at a dose of up to 50 mg and increased non -linear with a dose higher than 50 mg. The time IBANDRONIC acid reaches a plasma peak concentration between 0.5 and 2 hours (on average 1 hour), drinking at hunger and bioavailability is absolutely about 0.6%.

Distribution

After absorbing, ibandronic acid quickly combines with bones or excreted through urine. In humans, the apparent distribution voltage is at least 90 l and estimated at 40-50% of the dose separated from the cycle to add to the bone.

The ratio of cohesion with serum protein is about 85 - 87% (determined by in vitro at the treatment concentration) so the ability to interact with other drugs is low because it has combined with plasma proteins.

Metabolism

There is no evidence that ibandronic acid is metabolized in humans or animals.

Elimination

A part of ibandronic acid is absorbed from the circulation to the bone (about 40-50% in menopausal women) and the rest is excreted through the kidneys in a constant form. The ibandronic acid part is not absorbed from the excretion in the form of unchanged.

Before taking Joints of JointMeno 150mg Laboratorios liconsa prevents and treats osteoporosis after menopause (1 blister x 1 tablet)

How to use

oral medication.

Take medicine in the morning after waking up (at least 6 hours) and an hour before eating or drinking during the day (except for water) or before taking any medicine or supplement (including calcium) orally orally.

Take the whole pill with a full glass of water (180 - 240 ml) while the patient is sitting or standing in a straight position, not resting for 1 hour after taking the drug.

Patients should not chew and take pills because they are likely to cause mouth ulcers, pharynx and throat.

Only use filtered water to take medicine. Do not use some types of mineral water with high calcium concentration.

Dosage

normal dose

The recommended dose is a 150 mg film tablet per month. Should choose a fixed day in the month to drink.

Patients should take calcium supplements and/or vitamin D if the daily diet does not provide these 2 substances.

Special cases

kidney failure

There is no need to adjust the dose for patients with mild and medium renal impairment with creatinine clearance from 30 ml/min. Do not use ibandronic acid in patients with creatinine clearance below 30 ml/min due to clinical data restrictions.

Liver failure, the elderly

No dose adjustment.

Children

Do not use drugs for children, ibandronic acid has not been studied in children.

The optimal time for osteoporosis treatment with biphosphonate has not been set. It should be periodically reviewed on the continued treatment based on the benefits and potential risks in each patient, especially after 5 years of use.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do

do when overdose? However, based on the knowledge of this group of compounds, overdose can lead to side effects in the upper digestive tract (such as upper abdominal pain, indigestion, esophagitis, gastritis, or ulcers) or lower blood calcium. Milk or antacids should be used to combine with ibandronic acid that reduces toxicity and treats symptoms for other side effects. Due to the risk of esophageal stimulation, do not cause vomiting and patients should maintain vertical posture.

What to do when you forget 1 dose? After that, the patient returned to take 1 tablet/month on the selected day.

If there is 1 - 7 days left, it is the next drink, so wait for the next turn and take the medication as usual.

Do not take 2 pills within 7 days.

Side Effects

When using JointMeno, you may experience unwanted effects (ADR).

Serious side effects patients may encounter:

Allergic: rash, itching, face, lips, tongue and throat with shortness of breath, serious allergic reactions are life -threatening.

Severe pain in the chest, severe pain after eating or drinking, serious nausea, or vomiting.

Symptoms like influenza.

Pain or mouth/jaw sores.

Pain and eye inflammation (if prolonged).

New pain occurs, weak or uncomfortable in the thighs, hips or groin. This may be an abnormal early crack in the femur.

Other side effects:

Common, ADR> 1/100

Neurological: headache.

muscle muscle: muscle pain or muscle numbness, joint pain, back pain.

Cardiovascular: Hypertension. Digestive: heartburn, stomach pain, gastroesophageal reflux - esophagus, indigestion, nausea, diarrhea or constipation.

Other ADR: rash, influenza symptoms (fever, tremor, shudder, discomfort, fatigue, bone pain, muscle aches and joints).

Uncommon, 1/1000

Respiratory: Asthma.

nerve: drowsiness, dizziness.

digestion: flatulence. other ADR: weak people, back pain.

Rare, 1/10000

Hypersensitivity reactions: edema, lips that mouth, rash, itching.

digestive: duodenum, stomach pain.

Eye: Pain or eye inflammation.

Very rare, ADR

Anaphylaxis, jaw bone necrosis, Steven syndrome - Johnson.

Instructions on how to handle ADR

Notify the doctor the unwanted effects when using the drug.

Notify medical staff immediately if there is any serious side effects mentioned above, patients may need emergency medical treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Joints of joints contraindicated in the following cases:

Abnormalities in the esophagus such as narrow or esophageal spasms cause stomach empty.

Patients who are unable to stand or sit upright at least 60 minutes.

Low blood calcium concentration.

Hypersensitivity to ibandronic acid or any ingredient of the drug.

Renal failure (Creatinine clearance coefficient below 30 ml/minute).

Caution when using

bisphosphonate orally can cause irritation at the upper gastrointestinal mucosa and worsen the hidden diseases. Caution should be used when using ibandronic acid for patients who are having the above gastrointestinal problems (for example, Barrett’s esophagus, difficulty swallowing, other esophagus, gastritis, inflammation or ulcer).

With side effects such as inflammation, ulcer and esophageal corrosion, there have been some serious cases of hospitalization, some rare cases of bleeding or then narrow/perforation of the esophagus have been reported. The risk of serious side effects in the esophagus is almost higher in patients who do not comply with drugs and/or those who continue to take bisphosphonate after the symptoms of esophageal irritation.

Notify the doctor any signs or symptoms shows that the possibility of side effects in the esophagus, patients need to stop using ibandronic acid and need medical care if it is difficult to swallow, swallow pain, back pain or heartburn or bad heartburn.

While controlled clinical trials do not show an increase in the risk of peptic ulcer, reports after bringing the drug to the market show that the gastrointestinal ulcer occurs when taking bisphosphonate, some serious and complicated cases.

Hypoxemia: Patients with progressive blood calcium need to be treated before starting to use ibandronic acid. Bone metabolic disorders and other minerals should also be effectively treated. Provides adequate calcium and vitamin D very important for all patients.

Jaw bone necrosis: Jaw bone necrosis is usually caused by tooth extraction or local infection (including osteomyelitis), which has been reported in cancer patients using intravenous bishosphonate drugs. Most of these patients are being chemotherapy and using corticosteroids. Jaw bone necrosis has also been reported in some osteoporosis patients using oral bisphosphonate.

Consider appropriate dental testing and treatment before treatment with bisphosphonate in patients with risk factors simultaneously (for example, cancer, chemotherapy, radiation, using corticosteroids, poor dental hygiene).

During treatment, patients should avoid dental invasions if possible. For patients with jaw bone necrosis when treated with bisphosphonate, dental surgery can worsen this condition. For patients with dental procedures, there is no data on the discontinuation of bisphosphonate treatment, which reduces the risk of jaw bone necrosis.

Not typical femoral fracture: Subtrochanteric and long femoral femur (aphyseal) have been reported when using bisphosphonate, mainly in patients treated for long -term osteoporosis. Fractures usually occur on both sides, so the thigh bone should be checked in patients treated with bisphosphonate. The hard -to -heal fracture has also been reported. Consider stopping the treatment of bisphosphonate in patients suspected of not typical females based on assessing the risk benefits of the drug in each patient. During the treatment of bisphosphonate, patients should report any pain in the thigh, hip or groin and catch any patient with the above symptoms that must be assessed to be quite incomplete thigh fracture.

Galactose intolerance: Patients with problems with Galactose intolerance due to rare genetics, lactase deficiency or malposure lapp - galactose should not use this medication.

The ability to drive and operate machinery

The drug can cause headaches, dizziness, drowsiness, pain or eye inflammation. Be careful when driving and operating machinery during medication.

Pregnancy

There is no corresponding data on the use of ibandronic acid in pregnant women. Rat research shows some reproductive toxicity. The potential risk for unknown people. Therefore, drugs should not be used for pregnant women.

The period of breastfeeding

It is not known whether IBANDRONIC acid is excreted in breast milk or not. Research on nursing mice shows the appearance of low concentration of ibandronic acid in the milk after injecting drugs into veins. Use carefully in breastfeeding women.

Interactive drug

Notice to the doctor if the patient is taking any drug including non -prescribing drugs, especially:

The tonic contains calcium, magnesium, iron and aluminum because it can affect the effect of ibandronic acid. Bisphosphonate groups (such as ibandronic acid) can also cause stomach irritation. Therefore, be careful when using nonsteroidal analgesics and anti -inflammatory drugs during the time of jointmeno. Do not take medicine with food because it reduces the effectiveness of the drug. Only use water, do not use other types of water including milk.

Storage

Store at temperatures below 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.